Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fremanezumab - Teva Pharmaceutical Industries

Next Previous
Drug Profile

Fremanezumab - Teva Pharmaceutical Industries

Alternative Names: AJOVY; Anti-calcitonin gene-related peptide monoclonal antibody; Anti-CGRP monoclonal antibody; Fremanezumab-vfrm; LBR-101; PF-04427429; PF-4427429; RN-307; TEV-48125

Latest Information Update: 12 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Rinat Neuroscience
  • Developer Otsuka Pharmaceutical; Rinat Neuroscience; Teva Pharmaceutical Industries
  • Class Analgesics; Antimigraines; Monoclonal antibodies
  • Mechanism of Action Calcitonin gene-related peptide antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Migraine
  • Discontinued Cluster headache; Fibromyalgia; Headache; Interstitial cystitis

Most Recent Events

  • 04 Feb 2026 Registered for Migraine (Prevention, In children, In adolescents) in Canada (SC)
  • 14 Jan 2026 Efficacy and adverse events data from the phase III SPACE trial in Migrane released by Teva Pharmaceutical
  • 22 Dec 2025 Teva Pharmaceuticals completes a phase III trial for Migraine (Prevention, In children, In adolescents) (SC) in Canada, Finland, Germany, Israel, Italy, Netherlands, Poland, USA and Spain (NCT04530110)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top